Cause of death
| . | De novo AML (n = 393) . | sAML (n = 91) . | Overall (N = 484) . |
|---|---|---|---|
| Original disease | 227 (59.3%) | 36 (40.9%) | 263 (55.8%) |
| Infection | 75 (19.6%) | 23 (26.1%) | 98 (20.8%) |
| GVHD | 36 (9.4%) | 8 (9.1%) | 44 (9.3%) |
| Non-HSCT related | 14 (3.7%) | 3 (3.4%) | 17 (3.6%) |
| Other transplant related | 8 (2.1%) | 1 (1.1%) | 9 (1.9%) |
| MOF | 7 (1.8%) | 5 (5.7%) | 12 (2.5%) |
| Hemorrhage | 4 (1%) | 1 (1.1%) | 5 (1.1%) |
| Failure/rejection | 3 (0.8%) | 3 (3.4%) | 6 (1.3%) |
| IP | 3 (0.8%) | 1 (1.1%) | 4 (0.8%) |
| Other second malignancy | 3 (0.8%) | 2 (2.3%) | 5 (1.1%) |
| VOD | 2 (0.5%) | 1 (1.1%) | 3 (0.6%) |
| Cardiac toxicity | 1 (0.3%) | 0 (0%) | 1 (0.2%) |
| CNS toxicity | 0 (0%) | 4 (4.5%) | 4 (0.8%) |
| Missing | 10 | 3 | 13 |
| . | De novo AML (n = 393) . | sAML (n = 91) . | Overall (N = 484) . |
|---|---|---|---|
| Original disease | 227 (59.3%) | 36 (40.9%) | 263 (55.8%) |
| Infection | 75 (19.6%) | 23 (26.1%) | 98 (20.8%) |
| GVHD | 36 (9.4%) | 8 (9.1%) | 44 (9.3%) |
| Non-HSCT related | 14 (3.7%) | 3 (3.4%) | 17 (3.6%) |
| Other transplant related | 8 (2.1%) | 1 (1.1%) | 9 (1.9%) |
| MOF | 7 (1.8%) | 5 (5.7%) | 12 (2.5%) |
| Hemorrhage | 4 (1%) | 1 (1.1%) | 5 (1.1%) |
| Failure/rejection | 3 (0.8%) | 3 (3.4%) | 6 (1.3%) |
| IP | 3 (0.8%) | 1 (1.1%) | 4 (0.8%) |
| Other second malignancy | 3 (0.8%) | 2 (2.3%) | 5 (1.1%) |
| VOD | 2 (0.5%) | 1 (1.1%) | 3 (0.6%) |
| Cardiac toxicity | 1 (0.3%) | 0 (0%) | 1 (0.2%) |
| CNS toxicity | 0 (0%) | 4 (4.5%) | 4 (0.8%) |
| Missing | 10 | 3 | 13 |
CNS, central nervous system; IP, interstitial pneumonitis; MOF, multiorgan failure; VOD, veno-occlusive disease of the liver.